A61K 38/4846
Factor vii
Official title: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
A61K38/4846 (Factor vii) appears on 537 US grants and 990 published applications in this corpus.
Search patents in A61K- Granted patents
- 537
- Published applications
- 990
- Assignees
- 290
- Inventors
- 966
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 7 | 0 |
| 2000 | 10 | 0 |
| 2001 | 11 | 3 |
| 2002 | 6 | 13 |
| 2003 | 4 | 41 |
| 2004 | 5 | 30 |
| 2005 | 8 | 20 |
| 2006 | 9 | 32 |
| 2007 | 10 | 40 |
| 2008 | 11 | 34 |
| 2009 | 10 | 28 |
| 2010 | 15 | 40 |
| 2011 | 14 | 29 |
| 2012 | 15 | 26 |
| 2013 | 21 | 35 |
| 2014 | 28 | 78 |
| 2015 | 33 | 57 |
| 2016 | 33 | 66 |
| 2017 | 40 | 56 |
| 2018 | 31 | 61 |
| 2019 | 44 | 66 |
| 2020 | 39 | 56 |
| 2021 | 32 | 52 |
| 2022 | 27 | 35 |
| 2023 | 15 | 27 |
| 2024 | 19 | 27 |
| 2025 | 13 | 27 |
| 2026 | 8 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating intracranial hemorrhage and assessing efficacy21 Jul 2026US 12,685,763 B2Alexion Pharmaceuticals, Inc.
- Factor IX polypeptide formulations16 Jun 2026US 12,653,871 B2Bioverativ Therapeutics Inc.
- Isolated modified VP1 capsid protein of AAV59 Jun 2026US 12,649,766 B2
- Tissue factor-targeting CAR-NK and CAR-T cell therapy19 May 2026US 12,630,605 B2Ohio State Innovation Foundation
- High-activity blood coagulation factor XI mutant Ala570Thr21 Apr 2026US 12,605,430 B2Ruijin Hospital Shanghai Jiaotong University School of Medicine
- Human factor vii deletion constructs for treating cancer8 Oct 2026US 2026/0306592 A1The Cleveland Clinic Foundation
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
- Oligonucleotide Modulators Activating Factor VII Expression and Use Thereof in Treatment of Hemophilia10 Sep 2026US 2026/0265739 A1
- Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof3 Sep 2026US 2026/0258443 A1Kanglin Biotech (Hangzhou) Co., Ltd.
- Fitusiran for the treatment of hemophilia a and b in pediatric patients20 Aug 2026US 2026/0240891 A1Genzyme Corporation
Most cited
By later US patents
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Chitin hydrogels, methods of their production and use245US 6,124,273 AAmerican National Red Cross · 2000
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010